Treatment Methods Dry Form of Age Macular Degeneration — History and Prospects. Review
https://doi.org/10.18008/1816-5095-2023-3-398-404
Abstract
Age related macular degeneration is a leading cause of vision loss and an increasing problem of disability throughout the world among adults. That revue covers historical points, risk factors, pathogenesis, classification and current treatment ways of that pathology. The causes of age-related macular degeneration are not fully understood, in spite of keeping a great amount of knowledge at etiology, pathogenesis, diagnosis and modern types of treatment. The problem of age-related macular degeneration treatment has remained actual nowadays. Now, the medicine doesn’t have etiotropic treatment of AMD, because we still don’t know a definite etiologic factor of this developing disease. The main treatment for wet AMD is the injection of medications called anti-VEGF agents. Currently, treatment of dry age-related macular degeneration includes modification of risk factors (stop smoking, healthy life style and etc) and dietary supplements containing a combination of certain ingredients (vitamin C, vitamin E, zinc, copper, and lutein with zeaxanthin or beta-carotene) may be able to slow the progression of the disease. The disadvantage of current treatment methods is a narrow focus at one of the pathogenesis components or using as symptomatic therapy. The analysis of literature date has allowed noticing of using of an extracorporeal hemocorrection as perspective way at exploration of new methods of treatment of dry age-related macular degeneration.
About the Authors
A. N. Kulikov
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Kulikov Aleksey N., MD, Professor, head of the Ophthalmology department named after Professor V.V. Volkov
Academician Lebedev str., 6, Saint Petersburg, 194044
M. V. Zakharov
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Zakharov Mikhail V., PhD, deputy head of the Nephrology and efferent therapy department
Academician Lebedev str., 6, Saint Petersburg, 194044
A. A. Volozhev
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Volozhev Aleksandr A., adjunct of the Ophthalmology department named after Professor V.V. Volkov
Academician Lebedev str., 6, Saint Petersburg, 194044
References
1. Donders FC. Beiträge zur pathologischen Anatomie des Auges. Archiv Für Ophthalmologie. 1855;1(2):106–118.
2. Hutchinson SJ. Symmetrical central choroidoretinal disease occurring in senile persons. 1873. 3. Haab O. Erkrankungen der Macula lutea. Centralblat Augenheilkd. 1885;9:384–391.
3. Haab O. Atlas und Grundriss der Ophthalmoskopie und ophthalmoskopischen Diagnostik. Lehmann, 1908;2.
4. Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973 Sep;90(3):206–217. doi: 10.1001/archopht.1973.01000050208006.
5. Libman ES, Shakhova EV. State and dynamics of blindness and disability due to pathology of the organ of vision in Russia. Congress of ophthalmologists of Russia. 2000;7:209–214 (In Russ.).
6. Konyaev DA, Popova EB, Titov AA, Agarkov NM, Yablokov MM, Aksenov VV. The prevalence of eye diseases in the elderly population is a global problem of mo‑ dernity. Health care of the Russian Federation. 2021;65(1):62–68 (In Russ.). doi: 10.47470/0044-197X-2021-65-1-62-68.
7. Stahl A. The Diagnosis and Treatment of Age-Related Macular Degeneration. Dtsch Arztebl Int. 2020 Jul 20;117(29–30):513–520. doi: 10.3238/arztebl.2020.0513.
8. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106–116. doi: 10.1016/S2214-109X(13)70145-1. 10. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immunemediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001 Nov;20(6):705–732. doi: 10.1016/s1350-9462(01)00010-6.
9. De Jong PTVM. Elusive drusen and changing terminology of AMD. Eye (Lond). 2018 May;32(5):904–914. doi: 10.1038/eye.2017.298.
10. Gelfand BD, Ambati J. A Revised Hemodynamic Theory of Age-Related Macular Degeneration. Trends Mol Med. 2016 Aug;22(8):656–670. doi: 10.1016/j.molmed.2016.06.009. Epub 2016 Jul 13.
11. Friedman E, Smith TR, Kuwabara T. Senile choroidal vascular patterns and drusen. Arch Ophthalmol. 1963 Feb;69:220–230. doi: 10.1001/archopht.1963.00960040226014.
12. Xu W, Grunwald JE, Metelitsina TI, DuPont JC, Ying GS, Martin ER, Dunaief JL, Brucker AJ. Association of risk factors for choroidal neovascularization in agerelated macular degeneration with decreased foveolar choroidal circulation. Am J Ophthalmol. 2010 Jul;150(1):40–47.e2. doi: 10.1016/j.ajo.2010.01.041.
13. Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med. 2012 Aug;33(4):295–317. doi: 10.1016/j.mam.2012.04.005.
14. Koledintsev MN, Borodovitsyna OA. The role of correction of hemodynamic and microcirculation disorders in the treatment of age-related macular degeneration. Effective pharmacotherapy. 2014;30:6–11 (In Russ.).
15. Sarkisov K.G. O.V. Korkushko, A.S. Stupin Microcirculation and hemorheology in human aging. Problems of aging and longevity. 1998;7(3):269–278 (In Russ.).
16. Pimenov IV, Zaitseva NS, Volkolakova RYu. The state of hemostasis in patients with pathology of the retina and vascular tract of the eye. Annals of Ophthalmology. 1992;2:27–30 (In Russ.).
17. Sandhu R, Sivaprasad S, Shah SP, Adewoyin T, Chong NV. Pulsatile ocular blood flow in asymmetric age-related macular degeneration. Eye (Lond). 2007 Apr;21(4):506–511. doi: 10.1038/sj.eye.6702242.
18. Fedotova TS, Khokkanen VM, Trofimova SV. Pathogenetic aspects of age-related macular degeneration of the retina. Annals of Orenburg State University. 2014;12(173);325–330 (In Russ.).
19. Ratnapriya R, Chew EY. Age-related macular degeneration-clinical review and genetics update. Clin Genet. 2013 Aug;84(2):160–166. doi: 10.1111/cge.12206.
20. Schultz DW, Klein ML, Humpert AJ, Luzier CW, Persun V, Schain M, Mahan A, Runckel C, Cassera M, Vittal V, Doyle TM, Martin TM, Weleber RG, Francis PJ, Acott TS. Analysis of the ARMD1 locus: evidence that a mutation in HEMICEN‑ TIN-1 is associated with age-related macular degeneration in a large family. Hum Mol Genet. 2003 Dec 15;12(24):3315–3323. doi: 10.1093/hmg/ddg348.
21. Bolbas ZV, Vasilevskaya NA, Chikun EA. Age-related macular degeneration: vascular endothelial growth factor VEGF, chaperone RpE65 and ppAR family receptors as promising targets for drug therapy. Russian Medical News. 2010;1(3):37–45 (In Russ.).
22. Anderson DH, Ozaki S, Nealon M, Neitz J, Mullins RF, Hageman GS, Johnson LV. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol. 2001 Jun;131(6):767–781. doi: 10.1016/s0002-9394(00)00961-2.
23. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005 Apr 15;308(5720):419–421. doi: 10.1126/science.1110359.
24. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, San‑ Giovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Sci‑ ence. 2005 Apr 15;308(5720):385–389. doi: 10.1126/science.1109557.
25. Thakkinstian A, Han P, McEvoy M, Smith W, Hoh J, Magnusson K, Zhang K, Attia J. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet. 2006 Sep 15;15(18):2784–2790. doi: 10.1093/hmg/ddl220.
26. Fisher SA, Abecasis GR, Yashar BM, Zareparsi S, Swaroop A, Iyengar SK, Klein BE, Klein R, Lee KE, Majewski J, Schultz DW, Klein ML, Seddon JM, Santangelo SL, Weeks DE, Conley YP, Mah TS, Schmidt S, Haines JL, Pericak-Vance MA, Gorin MB, Schulz HL, Pardi F, Lewis CM, Weber BH. Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet. 2005 Aug 1;14(15):2257–2264. doi: 10.1093/hmg/ddi230.
27. Yang Z, Stratton C, Francis PJ, Kleinman ME, Tan PL, Gibbs D, Tong Z, Chen H, Constantine R, Yang X, Chen Y, Zeng J, Davey L, Ma X, Hau VS, Wang C, Harmon J, Buehler J, Pearson E, Patel S, Kaminoh Y, Watkins S, Luo L, Zabriskie NA, Bernstein PS, Cho W, Schwager A, Hinton DR, Klein ML, Hamon SC, Simmons E, Yu B, Campochiaro B, Sunness JS, Campochiaro P, Jorde L, Parmigiani G, Zack DJ, Katsanis N, Ambati J, Zhang K. Toll-like receptor 3 and geographic atrophy in agerelated macular degeneration. N Engl J Med. 2008 Oct 2;359(14):1456–1463. doi: 10.1056/NEJMoa0802437.
28. Black JR, Clark SJ. Age-related macular degeneration: genome-wide association studies to translation. Genet Med. 2016 Apr;18(4):283–289. doi: 10.1038/ gim.2015.70.
29. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001 Nov;132(5):668–681. doi: 10.1016/s0002-9394(01)01218-1.
30. Balashevich LI, Izmailov AS, Ulitina AYu. Modified clinical classification of agerelated macular degeneration. Ophthalmological journals. 2011;4(4):41–47 (In Russ.).
31. Maltsev DS, Kulikov AN, Chkhablani D, Kutik DS, Arsenov NV. Optical coherence tomography in the diagnosis and treatment of central serous chorioretinopa‑ thy. Annals of Ophthalmology. 2018;134(6):15–24 (In Russ.). doi: 10.17116/oftalma201813406115.
32. Handa JT, Bowes Rickman C, Dick AD, Gorin MB, Miller JW, Toth CA, Ueffing M, Zarbin M, Farrer LA. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. 2019 Jul 26;10(1):3347. doi: 10.1038/s41467-019-11262-1.
33. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Re‑ search Group; Writing Committee:; Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: TwoYear Results. Ophthalmology. 2020 Apr;127(4S):S135–S145. doi: 10.1016/j.ophtha.2020.01.029.
34. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008 Dec;115(12):2199–2205. doi: 10.1016/j.ophtha.2008.07.007.
35. Kulikov AN, Zakharov MV, Kacherovich PA, Volozhev AA, Shamrey DV, Kharitonova NN. Method for the treatment of ophthalmic diseases. Patent RU 2798002, 06.13.2023 (In Russ.).
36. Manuilov AS, Bardakov SN, Apchel AV, Belskih AN, Zakharov MV, Tishko VV, Ivanov AM. The experience of using cascade plasmofiltration in combined treatment with systemic lupus erythematosus on the background of programmed hemodialysis. Vestnik of the Russian Military Medical Academy. 2018;20(2):115–119 (In Russ.). doi: 10.17816/brmma12278.
37. Tishko VV, Belskikh AN, Tyrenko VV, Sizov DN, Sokolov AA, Kozlov KL, Oleksyuk IB, Shishkevich AN. Effect of efferent therapy on blood viscosity in patients with stable exertional angina after coronary angioplasty and stenting. Vestnik of the Russian Military Medical Academy. 2014;4:7–11 (In Russ.).
38. Blaha M, Rencova E, Langrova H, Studnicka J, Blaha V, Rozsival P, Lanska M, Sobotka L. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. Atheroscler Suppl. 2013 Jan;14(1):179–184. doi: 10.1016/j.atherosclerosissup.2012.10.023.
Review
For citations:
Kulikov A.N., Zakharov M.V., Volozhev A.A. Treatment Methods Dry Form of Age Macular Degeneration — History and Prospects. Review. Ophthalmology in Russia. 2023;20(3):398-404. (In Russ.) https://doi.org/10.18008/1816-5095-2023-3-398-404
Views:
695
Email this article 